Moreover, GLP-1R agonistshave the capacity to reduce body weight and prevent the obesity-associateddiabetes type 2, as demonstrated with the clinical use of liraglutideas an adjunct to a reduced-calorie diet and increased physical activityfor the long-term management of body weight in adult overweight patients. Here, GLP1R is linked to Obesity.